Kinetics of silica nanoparticles in the human placenta

Marie Sonnegaard Poulsen, Tina Mose, Lisa Leth Maroun, Line Mathiesen, Lisbeth Ehlert Knudsen, Erik Rytting

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 μg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10<sup>-6</sup> ± 1.56 × 10<sup>-6</sup> cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalNanotoxicology
Volume9
Issue numberS1
DOIs
StatePublished - May 1 2015

Fingerprint

Silicon Dioxide
Nanoparticles
Placenta
Silica
Kinetics
Cells
Mothers
Antipyrine
Choriocarcinoma
Confocal microscopy
Medical applications
Biocompatibility
Confocal Microscopy
Permeability
Assays
Cell Survival
Perfusion
Tissue
Safety
Imaging techniques

Keywords

  • BeWo cells
  • in vitro
  • Nanotoxicology
  • Placental perfusion
  • Transport

ASJC Scopus subject areas

  • Biomedical Engineering
  • Toxicology

Cite this

Poulsen, M. S., Mose, T., Maroun, L. L., Mathiesen, L., Knudsen, L. E., & Rytting, E. (2015). Kinetics of silica nanoparticles in the human placenta. Nanotoxicology, 9(S1), 79-86. https://doi.org/10.3109/17435390.2013.812259

Kinetics of silica nanoparticles in the human placenta. / Poulsen, Marie Sonnegaard; Mose, Tina; Maroun, Lisa Leth; Mathiesen, Line; Knudsen, Lisbeth Ehlert; Rytting, Erik.

In: Nanotoxicology, Vol. 9, No. S1, 01.05.2015, p. 79-86.

Research output: Contribution to journalArticle

Poulsen, MS, Mose, T, Maroun, LL, Mathiesen, L, Knudsen, LE & Rytting, E 2015, 'Kinetics of silica nanoparticles in the human placenta', Nanotoxicology, vol. 9, no. S1, pp. 79-86. https://doi.org/10.3109/17435390.2013.812259
Poulsen MS, Mose T, Maroun LL, Mathiesen L, Knudsen LE, Rytting E. Kinetics of silica nanoparticles in the human placenta. Nanotoxicology. 2015 May 1;9(S1):79-86. https://doi.org/10.3109/17435390.2013.812259
Poulsen, Marie Sonnegaard ; Mose, Tina ; Maroun, Lisa Leth ; Mathiesen, Line ; Knudsen, Lisbeth Ehlert ; Rytting, Erik. / Kinetics of silica nanoparticles in the human placenta. In: Nanotoxicology. 2015 ; Vol. 9, No. S1. pp. 79-86.
@article{98161a21fa0a47959d1fb51c9e816315,
title = "Kinetics of silica nanoparticles in the human placenta",
abstract = "The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 μg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9{\%} and 4.6 ± 2.4{\%} for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10-6 ± 1.56 × 10-6 cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.",
keywords = "BeWo cells, in vitro, Nanotoxicology, Placental perfusion, Transport",
author = "Poulsen, {Marie Sonnegaard} and Tina Mose and Maroun, {Lisa Leth} and Line Mathiesen and Knudsen, {Lisbeth Ehlert} and Erik Rytting",
year = "2015",
month = "5",
day = "1",
doi = "10.3109/17435390.2013.812259",
language = "English (US)",
volume = "9",
pages = "79--86",
journal = "Nanotoxicology",
issn = "1743-5390",
publisher = "Informa Healthcare",
number = "S1",

}

TY - JOUR

T1 - Kinetics of silica nanoparticles in the human placenta

AU - Poulsen, Marie Sonnegaard

AU - Mose, Tina

AU - Maroun, Lisa Leth

AU - Mathiesen, Line

AU - Knudsen, Lisbeth Ehlert

AU - Rytting, Erik

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 μg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10-6 ± 1.56 × 10-6 cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

AB - The potential medical applications of nanoparticles (NPs) warrant their investigation in terms of biodistribution and safety during pregnancy. The transport of silica NPs across the placenta was investigated using two models of maternal-foetal transfer in human placenta, namely, the BeWo b30 choriocarcinoma cell line and the ex vivo perfused human placenta. Nanotoxicity in BeWo cells was examined by the MTT assay which demonstrated decreased cell viability at concentrations >100 μg/mL. In the placental perfusion experiments, antipyrine crossed the placenta rapidly, with a foetal:maternal ratio of 0.97 ± 0.10 after 2 h. In contrast, the percentage of silica NPs reaching the foetal perfusate after 6 h was limited to 4.2 ± 4.9% and 4.6 ± 2.4% for 25 and 50 nm NPs, respectively. The transport of silica NPs across the BeWo cells was also limited, with an apparent permeability of only 1.54 × 10-6 ± 1.56 × 10-6 cm/s. Using confocal microscopy, there was visual confirmation of particle accumulation in both BeWo cells and in perfused placental tissue. Despite the low transfer of silica NPs to the foetal compartment, questions regarding biocompatibility could limit the application of unmodified silica NPs in biomedical imaging or therapy.

KW - BeWo cells

KW - in vitro

KW - Nanotoxicology

KW - Placental perfusion

KW - Transport

UR - http://www.scopus.com/inward/record.url?scp=84902115036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902115036&partnerID=8YFLogxK

U2 - 10.3109/17435390.2013.812259

DO - 10.3109/17435390.2013.812259

M3 - Article

C2 - 23742169

AN - SCOPUS:84902115036

VL - 9

SP - 79

EP - 86

JO - Nanotoxicology

JF - Nanotoxicology

SN - 1743-5390

IS - S1

ER -